Advances in Lung Transplantation - Royal Perth Hospital

More documents

Recommendations

Info

imary composite efficacy endpoint Month 12 Everolimus AZA (n=101) (n=112) p-value Primary composite endpoint: 21.8% 33.9% 0.05 - Decline in FEV1 >15% 15.8% 27.7% 0.03 - Graft loss 1.0% 5.4% 0.06 - Patient death 3.0% 8.9% 0.06 Month 24 Primary composite endpoint: 43.6% 44.6% ns - Decline in FEV1 >15% 34.7% 41.1% ns - Graft loss 7.9% 8.0% ns - Patient death 12.9% 13.4% ns
Steering Committee of the Australian and European Investigators in Lung Transplantation
Page 1 and 2: Advances in Lung Transplantation El
Page 3 and 4: Why is Lung Transplantation so diff
Page 5: Protoplasm Surgical Issues - late r
Page 8 and 9: Donor Availability 1. Impact of Don
Page 10 and 11: Maximizing the Utilization of Donor
Page 15 and 16: Treatment Volume status important -
Page 19 and 20: Improvements in Treatment and Preve
Page 21 and 22: CMV and Lung Transplantation CMV di
Page 23 and 24: Post Transplant CMV Prophylaxis Zam
Page 27 and 28: Long Term Problems Thorn in the sid
Page 29 and 30: The real meaning of BOS… BOS is a
Page 31 and 32: The real meaning of BOS… • BOS
Page 33 and 34: CNI Switch from CyA to Tacrolimus:
Page 35 and 36: hange in FEV1 (% pred) after switch
Page 37 and 38: Azithromycin Panbronchiolitis and C
Page 39 and 40: SURGERY Surgery for gastro- esophag
Page 41 and 42: OB: New Therapies are Needed Ration
Page 43 and 44: Azzola A, Havryk A, Chhajed P, Host
Page 45 and 46: Azzola A, Havryk A, Chhajed P, Host
Page 47 and 48: MMF 1.5gm bd 159 patients 40 deaths
Page 49: Randomized, double-blind study of e
Page 53 and 54: Actuarial survival post lung transp
Page 55: RPH First 8 Transplants How have th

Advances in Lung Transplantation - Royal Perth Hospital

Create successful ePaper yourself

Delete template?

Save as template?